RBC Europe’s Regeneron Pharmaceuticals REGN Stock Holding History

RBC Europe’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-335	Closed	-$203K	–	1029
2021 Q3	$203K	Buy	335 +10	+3%	+$6.21K	0.01%	301
2021 Q2	$182K	Buy	325 +300	+1,200%	+$152K	0.01%	329
2021 Q1	$11.8K	Sell	25 -43	-63%	-$20.9K	﹤0.01%	882
2020 Q4	$32.9K	Buy	68 +43	+172%	+$23.2K	﹤0.01%	606
2020 Q3	$14K	Hold	25	–	–	﹤0.01%	728
2020 Q2	$15.6K	Hold	25	–	–	﹤0.01%	674
2020 Q1	$12.2K	Hold	25	–	–	﹤0.01%	655
2019 Q4	$9.39K	Sell	25 -3	-11%	-$1.01K	﹤0.01%	814
2019 Q3	$7.77K	Buy	28 +25	+833%	+$7.4K	﹤0.01%	833
2019 Q2	$939	Hold	3	–	–	﹤0.01%	1013
2019 Q1	$1.23K	Hold	3	–	–	﹤0.01%	1017
2018 Q4	$1.12K	Hold	3	–	–	﹤0.01%	1021
2018 Q3	$1.21K	Hold	3	–	–	﹤0.01%	1063
2018 Q2	$1.03K	Hold	3	–	–	﹤0.01%	1079
2018 Q1	$1.03K	Hold	3	–	–	﹤0.01%	1065
2017 Q4	$1.13K	Hold	3	–	–	﹤0.01%	1078
2017 Q3	$1.34K	Buy	+3	New	+$1.43K	﹤0.01%	1070

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

RBC Europe's REGN Position: Q4 2021 in Review

RBC Europe sold out of Regeneron Pharmaceuticals (REGN) in Q4 2021, closing a stake of 335 shares — an estimated $203K sold.

RBC Europe first reported a position in REGN in Q3 2017 and held it in 17 quarters. The position peaked at $203K in Q3 2021. 1,078 funds tracked by Wall St. Rank hold REGN as of Q4 2021.

RBC Europe reported no remaining Regeneron Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
RBC Europe sold 335 Regeneron Pharmaceuticals shares in Q4 2021, an estimated $203K.
RBC Europe first reported a position in Regeneron Pharmaceuticals in Q3 2017 and held it in 17 quarters.
RBC Europe's Regeneron Pharmaceuticals position peaked at $203K in Q3 2021.
1,078 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2021.

Based on RBC Europe's 13F filing for Q4 2021, filed 14 Nov 2022.